Hagenström Kristina, Klinger Theresa, Stephan Brigitte, Augustin Matthias
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Psoriasis (Auckl). 2025 Jun 27;15:221-231. doi: 10.2147/PTT.S520267. eCollection 2025.
The management of psoriasis has undergone substantial evolution; however, the long-term prescription trends remain ambiguous. This study utilised a comprehensive data set of psoriasis drug prescriptions in Germany from 2010 to 2022, with the objective of evaluating the evolution of treatment modalities over time.
A retrospective longitudinal claims data analysis on systemic biologicals, non-biologicals, and topical treatments for psoriasis was conducted covering prescription rates, medical costs from the payer's perspective, and defined daily doses (DDDs).
Psoriasis prevalence increased slightly from 2.6% in 2010 to 2.7% in 2022. During this period, the proportion of persons receiving prescriptions rose from 55.0% in 2010 to 57.4% in 2022. By 2022, 46.2% of these persons received topical treatments, 13.0% systemic glucocorticosteroids (SCS), 6.7% non-biologicals, and 6.2% biologicals. Compared to 2010, the use of biologicals increased by 449.8%, SCS by 12.6%, non-biologicals by 13.9%, while topical treatments decreased by 3.2%. The annual cost per person treated with a biologic decreased from €16,315 to €13,412, while non-biologic and topical therapy costs increased slightly. Adalimumab was the most frequently prescribed systemic drug, followed by ustekinumab and secukinumab. The highest mean costs per-person were for ustekinumab (€19,717) and risankizumab (€16,986).
In more than a decade, the use of innovative systemic drugs, especially biologicals, in Germany has increased substantially. Despite their high cost, biologic expenses per person have slightly decreased over time.
银屑病的治疗方法已发生了重大演变；然而，长期处方趋势仍不明确。本研究利用了2010年至2022年德国银屑病药物处方的综合数据集，目的是评估治疗方式随时间的演变。
对银屑病的全身生物制剂、非生物制剂和局部治疗进行回顾性纵向索赔数据分析，涵盖处方率、从支付方角度看的医疗成本以及限定日剂量（DDD）。
银屑病患病率从2010年的2.6%略有上升至2022年的2.7%。在此期间，接受处方的人数比例从2010年的55.0%上升至2022年的57.4%。到2022年，这些人中46.2%接受局部治疗，13.0%接受全身糖皮质激素（SCS）治疗，6.7%接受非生物制剂治疗，6.2%接受生物制剂治疗。与2010年相比，生物制剂的使用增加了449.8%，SCS增加了12.6%，非生物制剂增加了13.9%，而局部治疗减少了3.2%。接受生物制剂治疗的人均年度成本从16315欧元降至13412欧元，而非生物制剂和局部治疗成本略有增加。阿达木单抗是最常处方的全身药物，其次是乌司奴单抗和司库奇尤单抗。人均成本最高的是乌司奴单抗（19717欧元）和瑞莎珠单抗（16986欧元）。
在十多年的时间里，德国创新全身药物尤其是生物制剂的使用大幅增加。尽管成本高昂，但人均生物制剂费用随着时间的推移略有下降。
